This year has illustrated a new pathway for the health sector and health companies are cashing in on this opportunity.
The COVID-19 pandemic has been a blessing in disguise in many ways. Where it has affected many industries and economies, the health companies have benefitted massively. From the vaccine making to other necessary health medicines, the pandemic has shaped a new era for healthcare sector.
Guardion Health Sciences, Inc. (GHSI) is a specialty health sciences firm that develops medical foods, medical devices, and clinically supported nutrition. The core focus of the company remains in the ocular health market.
In recent times, the health sciences stock has been hot topic in the market. The company has made some notable developments that had the investors buzzing.
Recently, Guardion announced the appointment of its new President and CEO, Bret Scholtes, who will take over the executive seat on Jan. 6, 2021. Mr. Scholtes is a veteran in the health industry for almost a decade and specializes in nutritional products. He served as the CEO of Omega Protein, a global nutritional firm, for 9 years.
Also, Scholtes will become a member of the Board of Directors of the company on the same day. The newly appointed CEO brings in a lot of industry experience to the firm, as he is a proven business acumen in the nutritional products industry.
The Chairman of the BoDs, Robert Weingarten believes that Scholtes with his extensive market expertise will help Guardion into a new era of growth. Bret is known for his efforts to sustain revenue and profit growth at Omega.
Moreover, the strategic policymaking in successful acquisitions remains a prominent accomplishment for Bret. All this experience and in-depth market expertise will help Guardion in both short and long-term growth.
The impact of Scholtes’ appointment is already recognizable with more investors pouring in the recent trading sessions.
Moreover, the company is working on its new vision energy drink, Epiq-V. On Dec. 16, the company reported that the new drink is under development for the U.S. and international markets.
Guardion has completed the initial testing phase and is working on the last phases of Epiq-V. The energy drink will target the adult market as a vision health product.
During the third quarter, the company reported revenues up to $253K, which increased by 57% from the same period in 2019. The medical food and medical device sales increased by 26% and 147%, respectively. While the cash balance by the end of Q3 was almost $9.8 million.
The third-quarter results reflect a bright future ahead. The average trading volume for Guardion Health Sciences, Inc. (GHSI) stock is almost 6.94 million—investors are jumping in numbers.
The health sciences firm is progressing quite well and expects to make bigger growth in the upcoming year. The demand for health products is high due to the increasing health issues worldwide. People are more sensitive due to COVID-19 pandemic and they are turning to notorious food.
The health industry has emerged as a helping hand for the human beings this year. The next year awaits this progress to turn into a much mature ecosystem. For investors, there is a massive opportunity in both near- and long-term growth. Guardion Health Sciences holds a potential to go big if the market goes bullish any time in 2021.